Cencora Reports Fiscal 2026 Fourth Quarter and Fiscal Year End Results
Business Wire•04/11/2026•06:35 ET
0
Key Highlights
- ➤Q4 revenue $88.4B, up 5.5%; adjusted diluted EPS $4.66, up 21.4%
- ➤Fiscal 2026 revenue $337.4B, up 5.0%; adjusted diluted EPS $17.97, up 12.3%
- ➤Fiscal 2027 adjusted diluted EPS expected at $19.40-$19.75, up 8%-10%
- ➤Cencora signed agreement to acquire American Oncology Network’s 350-plus-provider network
- ➤Quarterly dividend increased 10% to $0.66 per common share
Expert Statements
Robert P. Mauch, President and Chief Executive Officer of Cencora
“Fiscal 2026 was a pivotal year for Cencora, as we expanded our MSO platform through the acquisition of OneOncology, sharpened the focus of our portfolio and delivered record results. These actions laid the foundation and position us to move forward with significant momentum and clear strategic priorities.”
Robert P. Mauch, President and Chief Executive Officer of Cencora
“As we enter fiscal 2027, our new operating model is designed to strengthen our execution and provide visibility to our progress. By uniting our specialty businesses and elevating the voices of our customers, we are better able to advance our purpose and deliver sustained value for our shareholders.”
Cencora Reports Fiscal 2026 Fourth Quarter and Fiscal Year End Results
Fourth Quarter Revenue of $88.4 Billion up 5.5 Percent. GAAP Diluted EPS of $2.71 and Adjusted Diluted EPS of $4.66
Get started
Create a free account to read the full story.